Market Overview:
The global overactive bladder drug market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of overactive bladder, rising geriatric population, and growing demand for minimally invasive procedures. Based on type, the global overactive bladder drug market is segmented into anticholinergics, solifenacin, oxybutynin, darifenacin, fesoterodine, tolterodine trospium and others. Anticholinergics are expected to dominate the market during the forecast period owing to their high usage rates for treating overactive bladder symptoms. Based on application, the global overactive bladder drug market is segmented into idiopathic bladder overactivity and neurogenic bladder overactivity.
Product Definition:
Overactive Bladder Drug is a drug used to treat overactive bladder. It helps to control the symptoms of overactive bladder such as urine leakage, frequent urination, and urgency.
Anticholinergics:
Anticholinergics are drugs that block the action of acetylcholine, a chemical messenger that facilitates the transmission of signals from nerves to muscles. Blocking this pathway causes muscle relaxation and urine retention.
Solifenacin:
Solifenacin is an anti-inflammatory drug used to treat overactive bladder (OAB) and cystitis. It works by decreasing the activity of the nerve that causes pain in the bladder. Solifenacin tablets are white in color and are available as 5mg, 10mg, 15mg & 20 mg dosage forms.
The global OAB drug market was valued at around USD 1 billion in 2015.
Application Insights:
The application segment of the global market is categorized into neurogenic and idiopathic bladder overactivity. The neurogenic bladder overactivity segment held a larger share in 2017 owing to the rising prevalence of neurological disorders, such as Parkinson¢â‚¬â„¢s disease, multiple sclerosis, spinal cord injuries and brain injuries. As per the estimates reported by neurology clinics at Mayo Clinic, around 60 million people in North America are affected by various neurological disorders. Thus, increasing number of patients suffering from neurogenic bladder overactivity is expected to drive demand for OAB drugs during the forecast period.
The idiopathic category is anticipated to witness significant growth during the forecast period due to growing awareness about urinary symptoms among patients and healthcare professionals alike.
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare facilities, favorable reimbursement policies, and increasing prevalence of OAB and urge incontinence are some factors responsible for its largest share. In addition, the high adoption of technologically advanced products is also expected to drive growth during the forecast period.
Asia Pacific is anticipated to be one of the fastest growing regions during the forecast period owing to a large patient pool with symptoms suggestive of bladder obstruction or urinary leakage as well as rising awareness about overactive bladder disease treatment options among patients. Moreover, improving healthcare infrastructure along with an increase in government initiatives for raising awareness about OAB treatments will further boost growth during this period.
Growth Factors:
- Increasing prevalence of overactive bladder (OAB) due to aging population and rising obesity rates.
- Growing demand for effective and safe OAB treatments.
- Availability of novel drug therapies that provide better symptom relief than current treatments options.
- Increased awareness about the availability and benefits of OAB treatments among patients and healthcare professionals alike.
Scope Of The Report
Report Attributes
Report Details
Report Title
Overactive Bladder Drug Market Research Report
By Type
Anticholinergics, Solifenacin, Oxybutynin, Darifenacin, Fesoterodine, Tolterodine, Trospium, Others
By Application
Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity
By Companies
Astellas Pharma, Inc. (Japan), Pfizer, Inc. (US), Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (US), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Sanofi (France), Apotex, Inc. (Canada), Astellas Pharma, Inc. (Japan), Aurobindo Pharma Limited (India)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Overactive Bladder Drug Market Report Segments:
The global Overactive Bladder Drug market is segmented on the basis of:
Types
Anticholinergics, Solifenacin, Oxybutynin, Darifenacin, Fesoterodine, Tolterodine, Trospium, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Pharma, Inc. (Japan)
- Pfizer, Inc. (US)
- Teva Pharmaceutical Industries Limited (Israel)
- Allergan, Plc (Ireland)
- Medtronic plc (Ireland)
- Mylan N.V. (US)
- Endo International plc (Ireland)
- Hisamitsu Pharmaceutical Co., Inc. (Japan)
- Sanofi (France)
- Apotex, Inc. (Canada)
- Astellas Pharma, Inc. (Japan)
- Aurobindo Pharma Limited (India)
Highlights of The Overactive Bladder Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anticholinergics
- Solifenacin
- Oxybutynin
- Darifenacin
- Fesoterodine
- Tolterodine
- Trospium
- Others
- By Application:
- Idiopathic Bladder Overactivity
- Neurogenic Bladder Overactivity
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Overactive Bladder Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
An overactive bladder is a medical condition in which the bladder does not empty completely as it should. This can lead to urinary tract infections (UTIs), and may also cause problems with sex, because urine leakage during sexual activity can increase the risk of UTIs.
Some of the major players in the overactive bladder drug market are Astellas Pharma, Inc. (Japan), Pfizer, Inc. (US), Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (US), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Sanofi (France), Apotex, Inc. (Canada), Astellas Pharma, Inc. (Japan), Aurobindo Pharma Limited (India).
The overactive bladder drug market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Overactive Bladder Drug Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Overactive Bladder Drug Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Overactive Bladder Drug Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Overactive Bladder Drug Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Overactive Bladder Drug Market Size & Forecast, 2020-2028 4.5.1 Overactive Bladder Drug Market Size and Y-o-Y Growth 4.5.2 Overactive Bladder Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Anticholinergics
5.2.2 Solifenacin
5.2.3 Oxybutynin
5.2.4 Darifenacin
5.2.5 Fesoterodine
5.2.6 Tolterodine
5.2.7 Trospium
5.2.8 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Idiopathic Bladder Overactivity
6.2.2 Neurogenic Bladder Overactivity
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Overactive Bladder Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Overactive Bladder Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Anticholinergics
9.6.2 Solifenacin
9.6.3 Oxybutynin
9.6.4 Darifenacin
9.6.5 Fesoterodine
9.6.6 Tolterodine
9.6.7 Trospium
9.6.8 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Idiopathic Bladder Overactivity
9.10.2 Neurogenic Bladder Overactivity
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Anticholinergics
10.6.2 Solifenacin
10.6.3 Oxybutynin
10.6.4 Darifenacin
10.6.5 Fesoterodine
10.6.6 Tolterodine
10.6.7 Trospium
10.6.8 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Idiopathic Bladder Overactivity
10.10.2 Neurogenic Bladder Overactivity
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Anticholinergics
11.6.2 Solifenacin
11.6.3 Oxybutynin
11.6.4 Darifenacin
11.6.5 Fesoterodine
11.6.6 Tolterodine
11.6.7 Trospium
11.6.8 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Idiopathic Bladder Overactivity
11.10.2 Neurogenic Bladder Overactivity
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Anticholinergics
12.6.2 Solifenacin
12.6.3 Oxybutynin
12.6.4 Darifenacin
12.6.5 Fesoterodine
12.6.6 Tolterodine
12.6.7 Trospium
12.6.8 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Idiopathic Bladder Overactivity
12.10.2 Neurogenic Bladder Overactivity
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Anticholinergics
13.6.2 Solifenacin
13.6.3 Oxybutynin
13.6.4 Darifenacin
13.6.5 Fesoterodine
13.6.6 Tolterodine
13.6.7 Trospium
13.6.8 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Idiopathic Bladder Overactivity
13.10.2 Neurogenic Bladder Overactivity
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Overactive Bladder Drug Market: Competitive Dashboard
14.2 Global Overactive Bladder Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Astellas Pharma, Inc. (Japan)
14.3.2 Pfizer, Inc. (US)
14.3.3 Teva Pharmaceutical Industries Limited (Israel)
14.3.4 Allergan, Plc (Ireland)
14.3.5 Medtronic plc (Ireland)
14.3.6 Mylan N.V. (US)
14.3.7 Endo International plc (Ireland)
14.3.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
14.3.9 Sanofi (France)
14.3.10 Apotex, Inc. (Canada)
14.3.11 Astellas Pharma, Inc. (Japan)
14.3.12 Aurobindo Pharma Limited (India)